Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61393215 in Healthy Subjects (SAD and Food Effect)
NCT02812251Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rocavorexant in major depressive disorder (MDD) and anxiety disorders (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 14 days, Maximum Plasma Concentration at 4 days and 9 more. Started Jul 2016; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)anxiety disorders
Beyond the preview
Go deeper on NCT02812251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812251.